Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient

Clinical Kidney Journal

Volumn 6, Issue 1, 2013, Pages 122-

  Torregrosa, Jose Vicente ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; PARATHYROID HORMONE;

ADULT; CASE REPORT; CHRONIC KIDNEY DISEASE; FEMALE; HUMAN; HYPOCALCEMIA; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LABORATORY TEST; NOTE; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT;

EID: 84873358662     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs158     Document Type: Note

References (6)

1. de Beus E, Boer W. Denosumab for treatment of immobilization- related hypercalcaemia in a patient with advanced renal failure. Clin Kidney J 2012; 5: 566-571
2. Malberti F. Treatment of immobilization-related hypercalcaemia with denosumab. Clin Kidney J 2012; 5: 491-495
3. Dempster DW, Lambing CL, Kostenuik PJ et al. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 2012; 34: 521-536
4. Jamal S, Ljunggren O, Stehman-Breen C et al. Effects of denosumab on fractures and bone mineral density by level of kidney function. J Bone Miner Res 2011; 26: 1829-1835
5. Block GA, Bone HG, Fang L et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471-1479
6. McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012; 60: 626-628